跳转至内容
Merck
CN

1012780

USP

阿仑膦酸钠

United States Pharmacopeia (USP) Reference Standard

别名:

阿屈膦酸盐 钠 三水合物, 4-氨基-1-羟基-1-膦酸丁酯,单钠, MK-217

登录 查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C4H12NaNO7P2 · 3 H2O
化学文摘社编号:
分子量:
325.12
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

alendronate

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

[Na+].[H]O[H].[H]O[H].[H]O[H].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O

InChI

1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1

InChI key

DCSBSVSZJRSITC-UHFFFAOYSA-M

基因信息

human ... FDPS(2224)

正在寻找类似产品? 访问 产品对比指南

一般描述

阿仑膦酸钠是伯氨基双膦酸酯。

应用

阿仑膦酸钠USP参考标准品的预期用途是USP规定的指定质量测试和检测。

生化/生理作用

阿仑膦酸钠三水合物是一种骨吸收抑制剂;法尼基二磷酸合成酶抑制剂 (IC 50 = 460 nM);CD45 蛋白酪氨酸磷酸酶抑制剂。

分析说明

这些产品仅供测试和分析使用。它们不适用于人类或动物的给药,不可用于诊断、治疗或治愈任何疾病。

其他说明

可能适用相应的销售限制。

象形图

Exclamation mark

警示用语:

Warning

危险声明

预防措施声明

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

S O Işeri et al.
The Journal of endocrinology, 187(3), 399-406 (2006-01-21)
Alendronate sodium, a primary amino bisphosphonate, is widely used in the treatment of various diseases that are associated with bone resorption, such as postmenopausal osteoporosis and Paget's disease of bone. Although the adverse effects of biphosphonates on the gastrointestinal system
K Hatori et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 26(1), 303-313 (2014-09-23)
Mechanical loading at high frequency affects bone. Whether this also applies to osteoporotic bone, combined or not with bisphosphonate therapy, was investigated in this animal study through imaging. An anabolic effect of high-frequency loading on osteoporotic bone, however non-synergistic with
Caroline Houston et al.
Muscle & nerve, 49(4), 506-511 (2013-07-10)
Patients with DMD have low bone mineral density (BMD) and are at high risk for fractures. We examined changes in BMD and the effects of alendronate in DMD patients treated at our institution in the last decade. Retrospective cohort study
Kazuhiro Imai
Clinical interventions in aging, 8, 681-688 (2013-06-15)
Osteoporosis is a skeletal disorder characterized by loss of bone mass, decreased bone strength, and an increased risk of bone fracture. The disease progresses with age, especially in postmenopausal women. Japan is one of the most rapidly aging societies worldwide.
Nisarg J Shah et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(35), 12847-12852 (2014-08-20)
Traumatic wounds and congenital defects that require large-scale bone tissue repair have few successful clinical therapies, particularly for craniomaxillofacial defects. Although bioactive materials have demonstrated alternative approaches to tissue repair, an optimized materials system for reproducible, safe, and targeted repair

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持